Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
With improvements in response rate and survival seen for HER2 positive patients treated with
HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting
to increase antitumor effect shows promise. Patients with previously untreated localized HER2
positive esophageal, GE junction and gastric adenocarcinomas will be enrolled. Patients
meeting all inclusion/exclusion criteria will receive neoadjuvant treatment with concurrent
chemotherapy and radiation therapy beginning on day 1 of treatment. During the lead-in safety
portion, the optimal dose of lapatinib will be determined.